sever
investig
shown
pentoxifyllin
possess
broadspectrum
antivir
activ
rang
rna
dna
virus
howev
abil
inhibit
japanes
enceph
viru
jev
replic
yet
studi
present
studi
design
investig
antivir
activ
pentoxifyllin
jev
vitro
vivo
activ
pentoxifyllin
jev
evalu
vitro
use
cytopath
effect
inhibit
plaqu
reduct
assay
pentoxifyllin
abl
inhibit
jev
replic
dosedepend
manner
inhibitori
concentr
ic
gml
therapeut
index
ti
experi
studi
mechan
antivir
action
pentoxifyllin
use
vitro
translat
viral
mrna
suggest
drug
interfer
either
earli
late
protein
synthesi
like
exert
action
viru
assembl
andor
releas
furthermor
vivo
studi
show
pentoxifyllin
concentr
mgkg
mgkg
bodi
weight
abl
protect
complet
mice
challeng
lethal
dose
ld
jev
flavivirus
import
human
pathogen
caus
varieti
diseas
rang
mild
febril
ill
sever
enceph
haemorrhag
fever
among
japanes
enceph
viru
jev
neuropathogen
viru
commonli
infect
children
associ
acut
enceph
diseas
burden
japanes
enceph
je
increas
public
health
problem
averag
case
per
year
asia
despit
prospect
therapi
flaviviru
infect
encourag
led
unavail
specif
effici
antivir
agent
jev
rekindl
search
drug
inhibit
jev
replic
pentoxifyllin
methylxanthin
deriv
use
treat
human
vascular
diseas
despit
cardiovascular
drug
pentoxifyllin
also
demonstr
high
antivir
activ
herp
simplex
viru
vaccinia
viru
rotaviru
tickborn
enceph
viru
suggest
drug
also
broadspectrum
viru
inhibitori
properti
furthermor
pentoxifyllin
also
show
inhibit
human
immunodefici
viru
hiv
express
acut
chronic
infect
cell
vitro
human
peripher
blood
mononuclear
cell
howev
abil
pentoxifyllin
inhibit
jev
replic
cytotox
pentoxifyllin
ribavirin
evalu
use
trypan
blue
exclus
assay
briefli
ps
cell
grown
semiconflu
expos
five
differ
concentr
compound
day
viabl
cell
count
use
trypan
blue
dye
haemocytomet
concentr
compound
reduc
cell
growth
estim
cytotox
concentr
cc
effect
compound
cellular
prolifer
also
studi
describ
previous
ribavirin
known
inhibitor
flaviviru
replic
use
studi
standard
compar
result
experi
antivir
activ
pentoxifyllin
ribavirin
initi
determin
use
cpe
inhibit
assay
describ
previous
briefli
ps
cell
monolay
infect
multipl
infect
moi
viru
incub
h
c
end
incub
period
monolay
rins
steril
phosphatebuff
salin
pb
doubl
dilut
ribavirin
pentoxifyllin
begin
cc
ad
incub
day
experi
termin
viru
control
show
maximum
cpe
presenc
absenc
cpe
record
microscop
everi
day
plate
stain
use
crystal
violet
compar
viru
control
drug
control
experi
run
triplic
ensur
reproduc
antivir
activ
pentoxifyllin
note
screen
experi
confirm
plaqu
reduct
assay
describ
previous
briefli
ps
cell
grown
confluent
monolay
infect
moi
jev
adsorb
h
c
end
adsorpt
monolay
rins
l
mem
contain
vari
concentr
pentoxifyllin
gml
ribavirin
gml
ad
monolay
overlaid
mainten
medium
contain
molten
agaros
sigmaaldrich
st
loui
mo
appropri
control
includ
run
assay
incub
carri
c
day
end
incub
period
monolay
fix
stain
use
crystal
violet
plaqu
count
use
hand
len
experi
run
triplic
percentag
inhibit
plaqu
determin
use
follow
formula
inhibit
plaqu
viru
control
plaqu
drugtreat
plaqu
viru
control
antivir
activ
express
inhibitori
concentr
ic
concentr
compound
requir
inhibit
viral
plaqu
compar
viru
control
therapeut
potenti
specif
action
compound
calcul
therapeut
index
ti
ratio
cc
ic
understand
possibl
mechan
action
pentoxifyllin
relat
replic
cycl
jev
variou
vitro
experi
detail
carri
plate
contain
steril
coverslip
well
seed
cellswel
incub
attain
confluenc
monolay
infect
jev
moi
h
c
follow
incub
monolay
rins
replenish
medium
contain
fc
time
point
consid
h
post
infect
subsequ
h
post
infect
medium
harvest
determin
amount
extracellular
viru
releas
supernat
time
point
coverslip
contain
cell
also
remov
fix
chill
aceton
stain
immunofluoresc
assay
ifa
use
monoclon
antibodi
envelop
protein
jev
detect
cellbound
antigen
plate
seed
ps
cell
incub
c
overnight
jev
ad
monolay
incub
h
c
end
viru
adsorpt
monolay
rins
use
steril
pb
replenish
mem
contain
fc
time
point
consid
h
post
infect
start
h
time
point
pentoxifyllin
ad
h
post
infect
incub
c
supernat
fluid
harvest
respect
well
h
post
infect
fluid
divid
two
part
one
part
use
determin
viru
yield
tissu
cultur
infect
dose
tcid
ml
second
part
use
detect
presenc
solubl
jev
antigen
antigen
captur
enzymelink
immunosorb
assay
elisa
describ
elsewher
detect
cellbound
antigen
coverslip
cultur
fix
chill
aceton
min
c
stain
use
monoclon
antibodi
jev
clone
antimous
iggfluorescein
isothiocyan
fitc
conjug
indirect
ifa
understand
mechan
action
pentoxifyllin
vitro
translat
experi
carri
use
commerci
avail
transcend
tm
nonradioact
translat
detect
system
rabbit
reticulocyt
lysat
promega
madison
wi
ps
cell
monolay
adsorb
jev
moi
h
follow
adsorpt
monolay
rins
pentoxifyllin
ad
one
set
jevinfect
cell
incub
h
pentoxifyllin
concentr
ad
second
set
monolay
cultur
h
plate
incub
h
c
appropri
viru
cell
control
includ
end
incub
cell
treat
l
trizol
reagent
gibco
rockvil
md
viral
rna
extract
per
manufactur
instruct
extract
rna
subject
realtim
revers
transcriptas
polymeras
chain
reaction
rtpcr
use
sybr
green
chemistri
describ
previous
minor
modif
ensur
presenc
jev
rna
viral
rna
obtain
jevinfect
cell
encod
protein
subject
vitro
translat
use
commerci
kit
promega
describ
previous
complet
translat
reaction
l
product
subject
sodium
dodecyl
sulphat
polyacrylamid
gel
electrophoresi
sdspage
gel
electroblot
onto
polyvinyliden
fluorid
pvdf
membran
membran
react
specif
monoclon
antibodi
jev
develop
use
diaminobenzidin
h
initi
nontox
concentr
pentoxifyllin
determin
administ
intraperiton
mgkg
bodi
weight
compound
differ
group
n
per
group
swiss
albino
mice
mice
observ
period
day
loss
gain
weight
evid
toxic
compar
untreat
normal
mice
therapeut
potenti
pentoxifyllin
evalu
use
peripher
challeng
model
describ
previous
briefli
lethal
dose
ld
jev
inject
intraperiton
four
group
mice
n
bloodbrain
barrier
bbb
breach
h
later
use
steril
starch
follow
intraperiton
ip
administr
pentoxifyllin
mgkg
bodi
weight
twice
daili
three
group
mice
day
fourth
group
mice
n
serv
drug
control
fifth
group
mice
n
serv
sham
control
receiv
mem
intraperiton
starch
intracerebr
mice
observ
everi
day
day
post
infect
appear
symptom
death
end
observ
period
mice
surviv
infect
sacrif
brain
harvest
subject
jev
antigen
detect
ifa
viru
nucleic
acid
detect
realtim
pcr
viru
isol
describ
previous
cc
gml
pentoxifyllin
gml
ribavirin
antivir
activ
two
compound
initi
evalu
noncytotox
concentr
cc
jev
use
cpe
inhibit
assay
subsequ
evalu
plaqu
reduct
assay
dosedepend
reduct
viral
plaqu
fig
ic
gml
pentoxifyllin
gml
ribavirin
ti
ribavirin
ti
pentoxifyllin
suggest
compound
highli
activ
jev
first
step
understand
interact
jev
compound
experi
design
determin
kinet
viral
replic
vitro
note
earliest
appear
jev
antigen
infect
ps
cell
h
post
adsorpt
detect
ifa
fig
howev
first
infecti
progeni
viru
detect
supernat
medium
harvest
h
post
adsorpt
fig
cell
stain
earlier
time
point
h
posit
viral
antigen
supernat
harvest
yield
infecti
viru
base
find
conclud
singl
replic
cycl
jev
vitro
ps
cell
line
requir
h
complet
antivir
activ
pentoxifyllin
subsequ
investig
relat
kinet
jev
replic
nontox
concentr
pentoxifyllin
ad
variou
time
point
follow
entri
jev
ps
cell
experi
termin
follow
h
incub
pentoxifyllin
concentr
abl
inhibit
jev
replic
complet
ad
infect
monolay
h
post
infect
evidenc
absenc
viru
yield
solubl
antigen
howev
beyond
h
post
infect
pentoxifyllin
complet
inhibit
jev
replic
fig
intrigu
observ
presenc
viral
antigen
express
pentoxifyllinetr
cell
h
time
point
inhibit
viru
yield
fig
presenc
viral
antigen
note
pentoxifyllinetr
cell
h
fig
prompt
us
confirm
whether
translat
viral
protein
remain
unaffect
therefor
viral
rna
extract
seri
timepoint
experi
subject
vitro
translat
use
commerci
kit
viral
rna
obtain
jevinfect
cell
treat
pentoxifyllin
two
time
point
h
show
presenc
protein
react
jevspecif
monoclon
antibodi
western
blot
fig
observ
ip
administr
mgkg
bodi
weight
nontox
mice
whilst
mgkg
bodi
weight
show
sign
toxic
loss
weight
death
therefor
found
unsuit
use
studi
therapeut
potenti
pentoxifyllin
evalu
mice
use
peripher
challeng
model
three
group
n
per
group
swiss
albino
mice
infect
ld
jev
peripher
rout
administ
mgkg
bodi
weight
pentoxifyllin
ip
rout
twice
daili
mice
receiv
mgkg
bodi
weight
pentoxifyllin
show
protect
whilst
mice
receiv
mgkg
bodi
weight
pentoxifyllin
show
reduct
mortal
hand
mice
receiv
drug
succumb
enceph
within
day
mice
surviv
challeng
post
treatment
sacrif
brain
harvest
subject
viru
isol
detect
viral
antigen
viral
rna
rtpcr
infecti
viru
could
isol
brain
tissu
obtain
mice
surviv
challeng
similarli
viral
antigen
could
demonstr
brain
smear
immunofluoresc
stain
use
monoclon
antibodi
jev
howev
viral
nucleic
acid
detect
brain
homogen
rtpcr
suggest
viral
rna
present
brain
anim
surviv
jev
infect
follow
treatment
pentoxifyllin
use
agent
interfer
viral
replic
concomitantli
suppress
viral
infect
modul
immun
system
one
strategi
use
prevent
viral
infect
jev
infect
gener
rapid
inflammatori
respons
follow
entri
host
elev
level
tumour
necrosi
factoralpha
correl
poor
outcom
je
patient
pathophysiolog
central
nervou
system
inflamm
jev
may
attribut
rang
promot
viral
replic
evas
host
defenc
observ
rais
possibl
compound
capabl
block
could
reduc
sever
jev
infect
pentoxifyllin
known
inhibitor
product
furthermor
recent
studi
shown
pentoxifyllin
exhibit
antivir
activ
sever
acut
respiratori
syndrom
sar
viru
hiv
studi
therefor
design
investig
antivir
activ
pentoxifyllin
jev
vitro
vivo
present
studi
observ
pentoxifyllin
inhibit
jev
replic
postentri
cell
preliminari
experi
indic
compound
neither
interf
viral
adsorpt
possess
virucid
inactiv
properti
data
present
extent
antivir
activ
confirm
use
plaqu
reduct
assay
result
confirmatori
plaqu
reduct
assay
suggest
pentoxifyllin
ribavirin
abl
inhibit
jev
replic
dosedepend
manner
fig
signific
reduct
jev
plaqu
pentoxifyllin
concentr
well
cc
ic
gml
whilst
ic
ribavirin
gml
suggest
compound
possess
signific
inhibitori
potenti
jev
observ
compound
highli
activ
jev
ti
pentoxifyllin
ribavirin
respect
extens
vitro
studi
report
date
mechan
antivir
action
pentoxifyllin
absenc
inform
ask
two
crucial
question
pertain
antivir
activ
pentoxifyllin
probabl
stage
pentoxifyllin
inhibit
viru
replic
ii
late
addit
pentoxifyllin
infect
cell
delay
achiev
complet
inhibit
viru
replic
answer
question
use
experiment
approach
similar
describ
baginiski
et
al
pentoxifyllin
ad
interv
post
infect
complet
one
replic
cycl
jev
appear
pentoxifyllin
abl
inhibit
jev
replic
late
replic
cycl
assumpt
base
sever
find
obtain
studi
presenc
cellbound
antigen
detect
ifa
time
point
fig
suggest
protein
translat
unaffect
drug
ii
presenc
kda
vitro
translat
product
fig
obtain
h
h
post
infect
affirm
translat
viral
protein
unaffect
drug
iii
neither
infecti
viru
solubl
viral
antigen
could
detect
fig
supernat
drugtreat
cell
post
infect
taken
togeth
three
observ
suggest
pentoxifyllin
inde
abl
inhibit
jev
replic
stage
beyond
viral
translat
probabl
interf
assembl
andor
releas
virion
pentoxifyllin
interf
earli
late
protein
translat
detect
jev
antigen
ifa
drugtreat
cell
would
possibl
fig
establish
pentoxifyllin
abl
inhibit
jev
replic
vitro
investig
therapeut
potenti
vivo
mous
model
inde
drug
concentr
mgkg
mgkg
bodi
weight
abl
protect
mice
complet
lethal
challeng
ld
jev
although
viral
rna
demonstr
brain
drugtreat
mice
surviv
jev
infect
classic
sign
ill
observ
mice
indic
viru
cross
bbb
follow
ip
inject
fail
replic
presenc
compound
sinc
viral
antigen
demonstr
brain
smear
drugtreat
mice
ascertain
viral
rna
detect
brain
due
persist
infect
viru
isol
carri
use
monolay
observ
mice
surviv
infect
fail
demonstr
replic
viru
indic
lack
infecti
viru
brain
mice
surviv
treatment
pentoxifyllin
notwithstand
observ
must
emphasis
pentoxifyllin
potent
inhibitor
tnf
recent
report
jev
induc
apoptosi
cell
line
via
endoplasm
reticulum
stress
pathway
underli
mechan
neuron
apoptosi
jev
attribut
role
tumour
necrosi
factor
receptor
tnfr
superfamili
therefor
also
possibl
apart
exhibit
antijev
activ
pentoxifyllin
could
also
modul
tnf
respons
protect
mice
lethal
challeng
howev
studi
warrant
investig
immunomodulatori
role
pentoxifyllin
jev
infect
conclus
studi
present
unambigu
evid
antijev
activ
pentoxifyllin
necessit
evalu
compound
control
clinic
trial
